Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma

Disclosures: Disclosures This study was funded in part by Novartis and Onyx. JGB discloses research funding from Millenium, Onyx, Celgene, Jansen, Novartis and travel expenses provided by Millenium and Onyx. LLH discloses research funding from Onyx, honoraria from Onyx, and speaker’s bureau for Onyx, Genentech and Novartis. JRM discloses honoraria from Spectrum Pharmaceuticals and Bayer, consultancy for Spectrum Pharmaceuticals, speaker’s bureau for Spectrum Pharmaceuticals, Bayer and Pfizer, and travel expenses provided by Spectrum Pharmaceuticals and Bayer. ERA has no conflicts to disclose. JHE has no conflicts to disclose. RSO discloses honoraria from Bayer and Alexion and consultancy for Bayer and Alexion. JDH has no conflicts to disclose. IWF discloses research funding from Novartis.

Contributions: Author Contributions JGB was the principal investigator and takes primary responsibility for the paper. JGB was responsible for the conception and design of the work. JGB, LLH, JRM, ERA, JHE, RSO, and IWF enrolled patients on to the study. JGB, LLH, JRM, ERA, JHE, RSO and IWF contributed to the collection and assembly of data. JGB, JHE, JDH and IWF contributed to data analysis. All authors accept responsibility for the work, provided input on the manuscript and approved the final version of the manuscript.